The Benzimidazole SPR719 Shows Promising Concentration-Dependent Activity and Synergy against Nontuberculous Mycobacteria
Lian J. Pennings, Mike Marvin Ruth, Heiman Wertheim, Jakko van Ingen
Antimicrobial Agents and Chemotherapy · 2021-01
Abstract
The parent drug SPR720 could have a role especially in MAC pulmonary disease treatment. Further studies in dynamic models and trials are ongoing to advance clinical development.
MeSH terms
- Nontuberculous mycobacteria
- Benzimidazole
- Mycobacterium avium complex
- Medicine
- Pulmonary disease
- Pharmacology
- Microbiology
- Mycobacterium
- Tuberculosis
- Intensive care medicine